MAIA MAIA Biotechnology, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1878313 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-12.4%
TTM EPS YoY36.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-341.5%
ROA-148.3%
ROIC (approx.)-296.5%
Asset turnover—
Leverage & solvency
Liabilities / assets33.6%
Debt / equity0.00x
Current ratio3.41x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio1.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | $0 | $0 | $0 | — |
| R&D expense | $453,745 | $10.01M | $11.11M | $8.93M | $3.50M |
| SG&A expense | $9.72M | $6.95M | $9.07M | $6.14M | $4.29M |
| Operating income | -$24.27M | -$16.96M | -$20.18M | -$16.18M | -$7.79M |
| Interest expense | — | $57 | $6,863 | $6,967 | $827,539 |
| Pretax income | -$22.39M | -$23.25M | -$19.80M | -$15.80M | -$12.60M |
| Income tax | $2,000 | $2,000 | — | — | — |
| Net income | -$22.40M | -$23.25M | -$19.77M | -$15.77M | -$12.50M |
| EPS (basic) | -0.70 | -1.05 | -1.49 | -1.75 | -2.37 |
| EPS (diluted) | -0.70 | -1.05 | -1.49 | -1.75 | -2.37 |
| Weighted avg. shares (diluted) | 32.11M | 22.20M | 13.26M | 9.28M | 5.28M |
| Balance sheet | |||||
| Cash & equivalents | $0 | $0 | $7.15M | $10.95M | $10.57M |
| Current assets | $9.70M | $10.15M | $7.56M | $11.81M | $10.67M |
| Total assets | $9.70M | $10.16M | $7.57M | $12.02M | $11.33M |
| Current liabilities | $5.84M | $3.83M | $4.94M | $3.27M | $2.15M |
| Total liabilities | $7.33M | $6.52M | $7.09M | $3.51M | $2.15M |
| Shareholders' equity | $2.38M | $3.63M | $477,511 | $8.51M | $9.18M |
| Shares outstanding | 38.62M | 26.16M | 16.99M | 10.96M | 7.58M |
| Cash flow statement | |||||
| Operating cash flow | -$18.84M | -$15.70M | -$13.07M | -$12.10M | -$4.12M |
| Financing cash flow | $17.91M | $18.18M | $9.27M | $12.48M | $14.03M |
| Stock-based compensation | $2.63M | $1.91M | $3.09M | $2.32M | $2.72M |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.